Clinical Trials

Sponsor: Regeneron

Sponsor Study ID: REGN5093-M114-ONC-1864

Study Title: A Phase 1/2 Study of REGN5093 M114 (METxMET Antibody Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer

NCT Number: NCT04982224

Phase: I/II

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Lung

Study Objectives:

For more information about the trial above please contact the study team:

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)